Table 2 Signal strength of adverse events of pertuzumab at the system organ class (SOC) level in FAERS database

Blood and lymphatic system disorders

848

3.73 (3.48-4.00) ^a

3.57 (68673.87) ^a

1.84 (1.71) ^a

3.57 (3.37) ^a

Cardiac disorders

645

1.91 (1.76–2.06) ^a

1.87 (16674.70)

0.90 (0.83) ^a

1.87 (1.75)

Gastrointestinal disorders

2104

1.80 (1.72–1.89) ^a

1.69 (145491.33)

0.75 (0.72) ^a

1.69 (1.62)

Respiratory, thoracic and mediastinal disorders

1088

1.63 (1.53–1.73) ^a

1.58 (30352.29)

0.66 (0.62) ^a

1.58 (1.50)

Skin and subcutaneous tissue disorders

1132

1.42 (1.34–1.51) ^a

1.39 (19323.01)

0.47 (0.45) ^a

1.39 (1.32)

Hepatobiliary disorders

171

1.42 (1.22–1.65) ^a

1.41 (457.89)

0.50 (0.43) ^a

1.41 (1.25)

Vascular disorders

414

1.38 (1.25–1.52) ^a

1.37 (2273.62)

0.45 (0.41) ^a

1.37 (1.26)

Metabolism and nutrition disorders

393

1.29 (1.17–1.43) ^a

1.28 (1378.17)

0.36 (0.32) ^a

1.28 (1.18)

Investigations

1067

1.25 (1.18–1.34) ^a

1.24 (7998.15)

0.31 (0.29) ^a

1.24 (1.17)

Infections and infestations

961

1.25 (1.17–1.34) ^a

1.24 (6480.47)

0.31 (0.29) ^a

1.24 (1.17)

Immune system disorders

190

1.12 (0.97–1.29)

1.12 (75.71)

0.16 (0.14) ^a

1.12 (0.99)

Neoplasms benign, malignant and unspecified (incl cysts and polyps)

464

1.06 (0.97–1.17)

1.06 (131.92)

0.09 (0.08) ^a

1.06 (0.98)